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Cancer is a leading cause of death worldwide that is accounted
for 7.6 million deaths in 2008. More than 70% of all cancer
deaths occurred in low and middle income countries. Deaths
from cancer worldwide are projected to rise over 11 millionin 2030 as per WHO Cancer Fact sheet No 297 February
2011. Chemotherapy constitutes one of the modalities of
cancer treatment, either per se or in conjunction with other
treatment regimens. However, despite much progress in the
chemotherapy of cancerous diseases, anticancer drugs in cur-
rent clinical use generally do not address issues of excessive
organ toxicity, lack of cell speciﬁcity, short circulation half-
life, angiogenesis, metastasis and a pronounced tendency to
induce resistance in the target cells. Hence it is imperative to
develop a safe and effective drug candidate to save the lives
of million people worldwide.
Quinazolinone and its derivatives have drawn much atten-
tion because of their pharmacological activities particularly a
wide range of antitumor activities (Khalil et al., 2003). Anilino-
quinazolines in particular are potent inhibitors of growthJournal
2 D. Kumar et al.factor receptor tyrosine kinase (GFRTK) and have found
clinical applications in epidermal and vascular endothelial
GFR targets (Grunwald and Hidalgo, 2003). Quinazolinone
heterocycles possess diverse pharmacological activities
including antimycobacterial (Karel et al., 2001) antifungal
(Sawhney et al., 1980) antimalarial (Martin et al., 1964), anti-
hypertensive (Dienei et al.,1973), antihistaminic (Alagarsamy
et al., 2005, 2006), local anesthetic (Chandrasekhar
et al.,1986) anti-Parkinson (Naithani et al., 1989), antiviral
(Alagarsamy et al.,2004), and thymidylate synthase inhibitory
activities (Hennequin et al.,1996). The simple and condensed
quinazolinones are also known to exhibit analgesic
(Alagarsamy and Murugesan, 2007), anti-inﬂammatory
(Ravishankar et al., 1984) and anticonvulsant activities
(Hori et al.,1990). Interest in quinazolinones as anticancer
agents has further increased since the discovery of Raltitrexed
and Thymitaq (Fig. 1) and their activity as Thymidylate
enzyme inhibitors (Bavetsias et al., 1997). The compounds
containing imidazolone chromophore are known to have a
wide range of biological activities like anti-cancer, anti-
inﬂammatory, cardioactivity and angiotensin II receptor
antagonistic activity (Siamaki et al., 2008). A trisubstituted
imidazolone induces a high degree of apoptosis in human
leukemia cells and also has prominent cytotoxicity (Fang
et al., 2007; Lai et al., 2002). Inspired by these ﬁndings; we
attempted to synthesize novel quinazolinone derivatives fused
with imidazolone and to evaluate anticancer activities against
cervical cancer, breast cancer, leukemia and hepatocellular
carcinoma cell lines.2. Experimental
In the present study, fourteen novel congeneric series of qui-
nazolinone derivatives were synthesized as illustrated in2 2
3
3
Figure 1 Structural resemblance of Raltitre
Please cite this article in press as: Kumar, D. et al., Design, synthesis and cytotoxic ev
of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.07.001Scheme 1. The starting compound 3,5-dibromo anthranilic
acid (1) was synthesized according to the reported literature
procedure (Bogert, 1903) .Compound (1) was reacted with ace-
tic anhydride under anhydrous condition for 4 h. The interme-
diate (2) 6,8-dibromo-2-methyl-3,1-benzoxazin-4-one obtained
as a solid mass was used immediately for the next step (Misra
et al., 1995). Compound (2) was subjected to reﬂux conditions
with hydrazine hydrate in the presence of pyridine for 3 h to
get the building block 3-amino-6,8-dibromo-2-methyl-quinaz-
olin-4(3H)one (3) (Raghvendra et al., 2007). Differently substi-
tuted oxazolone derivatives were prepared according to the
reported literature (Cantello et al., 1994). Compound (3) was
subjected to reﬂux with various substituted oxazolone deriva-
tives in pyridine to yield the target compounds (Radadia
et al., 2006; Patel et al., 2003).
2.1. Materials
All the chemicals were of synthetic grade and commercially
procured from S.D. Fine Chem. Ltd., Mumbai, India. Melting
points were recorded on a Buchan capillary melting point
apparatus and are uncorrected. IR spectra were recorded on
a FT-IR8400S, Fourier Transform (Shimadzu) Infrared spec-
trophotometer using the KBr disk method. 1H NMR spectra
were recorded on a Perkin Elmer NMR Spectrophotometer-
300 MHz in DMSO-d6 using TMS as an internal standard.
Mass spectra were recorded on a Micro mass Q-TOF and
Shimadzu LCMS 2010A Mass spectrometer. Elemental
analysis was performed using a Perkin Elmer Auto system
XL Analyzer.
2.1.1. Synthesis of 6,8-dibromo-2-methyl-3,1-benzoxazin-4-one, 2
A mixture of 3,5-dibromo anthranilic acid 1 (0.05 mol) and
acetic anhydride (0.1 mol) was subjected to reﬂux under anhy-3
3
xed and Thymitaq with designed analogs.
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Scheme 1 Synthesis of imidazolone fused quinazolinone derivatives.
Synthesis of novel imidazolone fused quinazolinone derivatives 3drous conditions for 4 h. The excess of acetic anhydride was
then distilled off under reduced pressure and reaction mixture
was cooled to room temperature. The intermediate benzox-
azine-4-one obtained as a solid mass was used immediately
for the next step. Yield – 80%, m.p. 173–175 C.
2.1.2. Synthesis of 3-amino-6,8-dibromo-2-methylquinazolin-
4(3H)one, 3
Benzoxazin-4-one (2) (0.01 mol) was subjected to reﬂux condi-
tions with hydrazine hydrate (1.5 ml) in the presence of pyri-
dine (15 ml) for 3 h with occasional shaking. On cooling, thePlease cite this article in press as: Kumar, D. et al., Design, synthesis and cytotoxic ev
of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.07.001crystals formed were ﬁltered, washed with water and dried.
The crude product was recrystallized from ethyl acetate. Yield
– 81% m.p. 230–232 C.
2.1.3. Synthesis of 3-[4-(substituted benzylidene)-4,5-dihydro-
5-oxo-2-phenyl-1(H)imidazol-1-yl]-2-phenyl-6,8-disubstituted-
4(3H)-oxoquinazoline (4a–5d)
A mixture of 3-amino-6,8-dibromo-2-methylquinazolin-4(3H)
one (3, 0.01 mol) and differently substituted oxazolone deriva-
tives (0.01 mol) in pyridine (30 ml) was subjected to reﬂux for
four hours. After cooling, the resultant mixture was pouredaluation of novel imidazolone fused quinazolinone derivatives. Arabian Journal
4 D. Kumar et al.over crushed ice and the contents were acidiﬁed with dilute
hydrochloric acid to remove excess pyridine. The solids were
ﬁltered, washed with cold water, dried and recrystallized from
ethanol.
2.1.3.1. 3-(2-(Furan-2-yl)-4-((furan-2-yl)methylene)-4,5-dihy-
dro-5-oxoimidazol-1-yl)-2-methyl-6,8-dibromoquinazolin-4(3H)-
one (4a). Yield – 81.33%; m.p. 214–215 C. IR (KBr cm1) t
max: 3306 (NAN), 3205 (C‚CAH) , 3074 (CAHAAr), 2889
(CACH3) 1666 (C‚O imidazoline ring), 1622 (C‚O quinazo-
line ring), 1527 (C‚N), 1161 (CAOAFuran), 719 (CABr); 1H
NMR (300 MHz, CDCl3, d ppm: 7.9–7.70 (d, 2H, QNZ-
ArAH), 6.64–7.29, 7.74–8.30 (m, 6H, FuranAH), 6.61 (s,
1H, C‚CAH), 2.75 (s, 3H, CH3); EI-MS (m/z): 544 [M]
+.
Anal. Calcd for C21H12Br2N4O4: C, 46.35; H, 2.22; N, 10.30;
Found: C, 46.05; H, 2.62; N, 10.60.
2.1.3.2. 3-(2-(Furan-2-yl)-4,5-dihydro-5-oxo-4-phenylallylidene)-
imidazol-1-yl)-6,8-dibromo-2-methylquinazolin-4(3H)-one (4b).
Yield – 80.21%; m.p. 220–222 C. IR (KBr cm1) t max:
3306 (NAN), 3205 (C‚CAH) , 3074 (CAHAAr), 2889
(CACH3), 1666 (C‚O imidazoline ring), 1622 (C‚O quinaz-
oline ring), 1506 (C‚N), 1161 (CAOAFuran), 719 (CABr);
1H NMR (300 MHz, CDCl3, d ppm: 7.10,7.42 (d, 2H,
QNZAArAH), 7.43–8.12 (m, 5H, ArAH), 6.72 (d, 2H,
C‚CAH), 6.64–6.65 (m, 3H, FuranAH), 2.75 (s, 3H, CH3);
EI-MS (m/z): 581 (M++1). Anal. Calcd for C25H16Br2N4O3:
C, 51.75; H, 2.78; N, 9.66; Found: C, 51.40; H, 2.97; N, 9.22.
2.1.3.3. 3-(4-Benzylidene-2-(furan-2-yl)-4,5-dihydro-5-oxo-imi-
dazol-1-yl)-6,8-dibromo-2-methyl quinazolin-4(3H)-one (4c).
Yield – 80.21%; m.p. 210–213 C. IR (KBr cm1) t max:
3308 (NAN), 2872 (C‚CAH) , 3248 (CAHAAr), 3076
(CACH3), 1666 (C‚O imidazoline ring), 1624 (C‚O quinaz-
oline ring), 1508 (C‚N), 1163 (CAOAFuran), 788 (CABr);
1H NMR (300 MHz, CDCl3, d ppm: 7.29–8.34 (m, 5H,
ArAH), 7.1, 7.26 (d, 2H, QNZAArAH), 7.01 (s, 1H,
C‚CAH), 6.64–7.26 (m, 3H, FuranAH), 2.7 (s, 3H, CH3);
EI-MS (m/z): 554 [M]+. Anal. Calcd for C23H14Br2N4O3: C,
49.85; H, 2.55; N, 10.11; Found: C, 49.45; H, 2.14; N, 10.50.
2.1.3.4. 3-(4-(2-Chlorobenzylidene)-2-(furan-2-yl)-4,5-dihy-
dro-5-oxoimidazol-1-yl)-6,8-dibromo-2-methylquinazolin-
4(3H)-one (4d). Yield – 86.65%; m.p. 234–236 C; IR (KBr
cm1) t max: 3306 (NAN), 3425 (C‚CAH) , 3198
(CAHAAr), 3076 (CACH3), 1666 (C‚O imidazoline ring),
1624 (C‚O quinazoline ring), 1589 (C‚N), 1114
(CAOAFuran), 719 (CABr); 1H NMR (300 MHz, CDCl3, d
ppm: 7.74–8.33 (m, 4H, ArAH), 7.0, 7.29 (d, 2H,
QNZAArAH), 6.83 (s, 1H, C‚CAH), 6.63–6.97 (m, 3H,
FuranAH), 2.75 (s, 3H, CH3); EI-MS (m/z): 588 [M]
+. Anal.
Calcd for C23H13Br2ClN4O3: C, 46.93; H, 2.23; N, 9.52;
Found: C, 46.50; H, 2.44; N, 9.34.
2.1.3.5. 3-[4-(4-Methoxybenzylidene)-4,5-dihydro-5-oxo-2phe-
nyl-1(H)imidazol-1-yl]-6,8-dibromo-2-phenyl-4(3H)-oxo-qui-
nazoline (4e). Yield – 83.04%; m.p. 209–211 C; IR (KBr
cm1) t max: 3306 (NAN), 3213 (C‚CAH) , 3074
(CAHAAr), 2904 (CACH3), 1668 (C‚O imidazoline ring),
1622 (C‚O quinazoline ring), 1157 (CAOAFuran), 1510
(C‚N), 719 (CABr); 1H NMR (300 MHz, CDCl3, d ppm:
7.29–8.34 (m, 4H, ArAH), 7.19 (s, 1H, C‚CAH), 6.64–7.26Please cite this article in press as: Kumar, D. et al., Design, synthesis and cytotoxic ev
of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.07.001(m, 3H, FuranAH), 6.57–7.28 (d, 2H, QNZAArAH), 3.85
(s, 3H, OCH3), 2.75 (s, 3H, CH3); EI-MS (m/z): 584(M
+).
Anal. Calcd for C24H16Br2N4O4: C, 49.34; H, 2.76; N, 9.59;
Found: C, 49.01; H, 2.47; N, 9.88.
2.1.3.6. 3-(4-(4-(Dimethylamino)benzylidene)-2-(furan-2-yl)-
4,5-dihydro-5-oxoimidazol-1-yl)-6,8-dibromo-2-methylquinazo-
lin-4(3H)-one (4f). Yield – 84.02%; m.p. 217–219 C; IR
(KBr cm1) t max: 3433 (NAN), 3360 (C‚CAH) , 3261
(CAHAAr), 3010 (CACH3), 1664 (C‚O imidazoline ring),
1622 (C‚O quinazoline ring), 1587 (C‚N), 1161
(CAOAFuran), 719 (CABr); 1H NMR (300 MHz, CDCl3, d
ppm: 8.07–8.13 (m, 4H, ArAH), 7.38 (s, 1H, C‚CAH),
6.74–7.70 (d, 2H, QNZAArAH), 6.61–6.71 (m, 3H,
FuranAH), 3.10 (s, 6H, 2·NCH3), 2.75 (s, 3H, CH3); EI-MS
(m/z): 597 (M+). Anal. Calcd for C25H19Br2N5O3: C, 50.27;
H, 3.21; N, 11.73; Found: C, 50.65; H, 3.53; N, 11.32.
2.1.3.7. 3-(4-(3-Chlorobenzylidene)-2-(furan-2-yl)-4,5-dihydro-
5-oxoimidazol-1-yl)-6,8-dibromo-2-methylquinazolin-4(3H)-one
(4g). Yield – 82.0%; m.p. 225–228 C; IR (KBr cm1) t max:
3431 (NAN), 3350 (C‚CAH) , 3232 (CAHAAr), 3076
(CACH3), 1666 (C‚O imidazoline ring), 1622 (C‚O quinaz-
oline ring), 1568 (C‚N), 1163 (CAOAFuran), 719 (CABr);
1H NMR (300 MHz, CDCl3, d ppm: 7.26–8.12 (m, 4H,
ArAH), 6.66–7.16 (d, 2H, QNZAArAH), 6.64–6.65 (m, 3H,
FuranAH), 6.33 (s, 1H, C‚CAH), 2.75 (s, 3H, CH3); EI-
MS (m/z): 588 (M+). Anal Calcd for C23H13Br2 ClN4O3: C,
46.93; H, 2.23; N, 9.52; Found: C, 46.62; H, 2.60; N, 9.10.
2.1.3.8. 3-(4-(2-Hydroxybenzylidene)-2-(furan-2-yl)-4,5-dihydro-
5-oxoimidazol-1-yl)-6,8-dibromo-2-methylquinazolin-4(3H)-one
(4h). Yield – 85.0%; m.p. 198–200 C; IR (KBr cm1) t max:
3473 (NAN), 3400 (C‚CAH), 3344 (CAHAAr), 3105
(CACH3), 1668 (C‚O imidazoline ring), 1622 (C‚O quinaz-
oline ring), 1568 (C‚N), 1163 (CAOAFuran), 719 (CABr);
1H NMR (300 MHz, CDCl3, d ppm: 8.98 (s, 1H, OH), 7.49–
8.98 (m, 4H, ArAH), 7.48 (s, 1H, C‚CAH), 7.26–7.47 (d,
2H, QNZAArAH), 6.67–6.98 (m, 3H, FuranAH), 2.75 (s,
3H, CH3); EI-MS (m/z): 571 (M
++1). Anal Calcd for C23H14-
Br2N4O4: C, 48.45; H, 2.47; N, 9.83; Found: C, 48.05; H, 2.17;
N, 9.43.
2.1.3.9. 3-(4-(3-Methoxybenzylidene)-2-(furan-2-yl)-4,5-dihy-
dro-5-oxoimidazol-1-yl)-6,8-dibromo-2-methylquinazolin-
4(3H)-one (4i). Yield – 87.0%; m.p. 233–235 C; IR (KBr
cm1) t max: 3308 (NAN), 3473 (C‚CAH) , 3400
(CAHAAr), 3105 (CACH3), 1668 (C‚O imidazoline ring),
1624 (C‚O quinazoline ring), 1568 (C‚N), 1163
(CAOAFuran), 721 (CABr); 1H NMR (300 MHz, CDCl3, d
ppm: 7.35–8.33 (m, 4H, ArAH), 6.97 (s, 1H, C‚CAH),
6.66–7.33 (d, 2H, QNZAArAH), 6.64–6.66 (m, 3H,
FuranAH), 3.89 (s, 3H, OCH3), 2.75 (s, 3H, CH3); EI-MS
(m/z): 584 (M+). Anal Calcd for C24H16Br2N4O4: C, 49.34;
H, 2.76; N, 9.59; Found: C, 49.69; H, 2.30; N, 9.10.
2.1.3.10. 3-(4-(3-Nitrobenzylidene)-2-(furan-2-yl)-4,5-dihydro-
5-oxoimidazol-1-yl)-6,8-dibromo-2-methylquinazolin-4(3H)-one
(4j). Yield – 80.0%; m.p. 230–232 C; IR (KBr cm1) t max:
3309 (NAN), 3213 (C‚CAH), 3076 (CAHAArCAHAAr),
2881 (CACH3), 1668 (C‚O imidazoline ring), 1622 (C‚O
quinazoline ring), 1568 (C‚N), 1163 (CAOAFuran), 719aluation of novel imidazolone fused quinazolinone derivatives. Arabian Journal
Table 1 In-vitro anti cancer screening of the synthesized
compounds against various human cancer cell lines.
Compound no. IC50 ± SE (lM)
HeLaa MCF-7b HL-60c HepG2d
4a 78.12 ± 0.76 89.1 ± 0.91 75.2 ± 1.2 71.1 ± 0.65
4b 67.45 ± 0.10 81.2 ± 0.87 56.1 ± 0.3 67.23 ± 0.55
4c 81.4 ± 0.14 89.7 ± 0.52 89.1 ± 0.7 91.5 ± 0.78
4d 79.1 ± 0.12 76.76 ± 0.34 85.2 ± 0.4 77.2 ± 0.65
4e 41.8 ± 0.20 8.9 ± 0.29 6.6 ± 0.51 9.6 ± 0.45
4f 67.7 ± 0.44 56.13 ± 0.4 29.7 ± 0.74 45.2 ± 0.67
4g 71.4 ± 0.50 51.4 ± 0.32 45.7 ± 0.80 47.1 ± 0.41
4h 60.1 ± 0.41 61.8 ± 0.71 46.9 ± 0.21 40.2 ± 1.10
4i 57.1 ± 0.78 46.2 ± 0.88 17.4 ± 0.11 32.8 ± 0.91
4j 81.1 ± 0.67 70.1 ± 0.18 65.1 ± 0.13 76.1 ± 0.41
5a 89.1 ± 0.90 79.2 ± 0.34 46.1 ± 0.12 65.1 ± 0.50
5b 72.5 ± 0.43 51.9 ± 0.79 34.6 ± 0.31 41.7 ± 0.56
5c 75.7 ± 0.76 59.4 ± 0.61 56.1 ± 0.50 51.1 ± 0.67
5d 78.2 ± 0.30 63.1 ± 0.78 64.2 ± 0.81 52.6 ± 0.12
Cisplatin 34.9 ± 0.32 26.2 ± 0.68 6.9 ± 0.51 22.1 ± 0.19
a HeLa (cervical cancer).
b MCF-7 (breast cancer).
c HL-60 (human promyelocytic leukemia).
d HepG2 (hepatocellular carcinoma).
Synthesis of novel imidazolone fused quinazolinone derivatives 5(CABr); 1H NMR (300 MHz, CDCl3, d ppm: 7.70–8.34
(m, 4H, ArAH), 7.53 (s, 1H, C‚CAH), 7.26–7.48 (d, 2H,
QNZAArAH), 6.64–7.16 (m, 3H, FuranAH), 2.75 (s, 3H, CH3);
EI-MS (m/z): 599 (M+). Anal Calcd for C23H13Br2N5O5: C,
46.10; H, 2.19; N, 11.69; Found: C, 46.40; H, 2.48; N, 11.88.
2.1.3.11. 3-(-4-(Furan-2-yl)-4-methylene)-4,5-dihydro-2-methyl-
5-oxoimidazol-1-yl)-6,8-dibromo-2-methylquinazolin-4(3H)-one
(5a). Yield – 82.0%; m.p. 246–248 C; IR (KBr cm1) t max:
3448 (NAN), 3203 (CAHAAr), 3076 (CACH3), 1666 (C‚O
imidazoline ring), 1622 (C‚O quinazoline ring), 1585
(C‚N), 721 (CABr); 1H NMR (300 MHz, CDCl3, d ppm:
7.08 (s, 1H, C‚CAH), 7.00–8.33 (d, 2H, QNZAArAH),
6.63–6.65 (m, 3H,furan H), 2.75 (s, 3H, CH3 of QNZ), 2.58
(s, 3H, CH3 of imidazole); EI-MS (m/z): 492 (M
+). Anal Calcd
for C18H12Br2N4O3: C, 43.93; H, 2.46; N, 11.38; Found: C,
43.60; H, 2.78; N, 11.04.
2.1.3.12. 3-(4-Benzylidene-4,5-dihydro-2-methyl-5-oxoimidazol-
1-yl)-6,8-dibromo-2-methyl quinazolin-4(3H)-one (5b). Yield –
83.0%; m.p. 238–240 C; IR (KBr cm1) t max: 3306 (NAN),
3203 (CAHAAr), 3076 (CACH3) 2872 (C‚CAH) , 1666
(C‚O imidazoline ring), 1622 (C‚O quinazoline ring), 1508
(C‚N), 788 (CABr); 1H NMR (300 MHz, CDCl3, d ppm:
7.70–8.34,6.64–7.26 (m, 5H, ArAH), 7.29–7.48 (d, 2H,
QNZAArAH), 7.15 (s, 1H, C‚CAH), 2.75 (s, 3H, CH3 of
QNZ), 1.59 (s, 3H, CH3 of imidazole); EI-MS (m/z): 503
(M++1). Anal Calcd for C20H14Br2 N4O2: C, 47.84; H,
2.81; N, 11.16; Found: C, 47.30; H, 2.81; N, 11.39.
2.1.3.13. 3-(4-(2-Chlorobenzylidene)-4,5-dihydro-2-methyl-5-
oxoimidazol-1-yl)-6,8-dibromo-2-methylquinazolin-4(3H)-one
(5c). Yield – 83.0%; m.p. 240–242 C; IR (KBr cm1) t max:
3331 (NAN), 3230,3246 (CAHAAr), 3230 (CACH3), 1666
(C‚O imidazoline ring), 1629 (C‚O quinazoline ring), 1543
(C‚N), 788 (CABr), 719,788, 653,596,546 (Aromatic ring
vibration); 1H NMR (300 MHz, CDCl3, d ppm: 7.70–
8.34,6.64–7.26 (m, 4H, ArAH), 7.59 (s, 1H, C‚CAH), 7.29–
7.48 (d, 2H, QNZAArAH), 2.75 (s, 3H, CH3 of QNZ), 1.55
(s, 3H, CH3 of imidazole); EI-MS (m/z): 536 (M
+). Anal.
Calcd for C20H13Br2Cl N4O2: C, 44.77; H, 2.44; N, 10.04;
Found: C, 44.39; H, 2.80; N, 10.44.
2.1.3.14. 3-(4-(3-Chlorobenzylidene)-4,5-dihydro-2-methyl-5-
oxoimidazol-1-yl)-6,8-dibromo-2-methylquinazolin-4(3H)-one
(5d). Yield – 84.5%; m.p. 244–245 C; IR (KBr cm1) t max:
3431 (NAN), 3306 (C‚CAH), 3203 (CAHAAr), 3076
(CACH3), 1666 (C‚O imidazoline ring), 1622, 1602 (C‚O
quinazoline ring), 1543 (C‚N), 721 (CABr); 1H NMR
(300 MHz, CDCl3, d ppm: 7.26–8.33 (m, 4H, ArAH), 6.88
(s, 1H, C‚CAH), 6.62–7.21 (d, 2H, QNZAArAH), 2.75 (s,
3H, CH3 of QNZ), 1.59 (s, 3H, CH3 of imidazole); EI-MS
(m/z): 537 (M++1). Anal. Calcd for C20H13Br2Cl N4O2: C,
44.77; H, 2.44; N, 10.04; Found: C, 44.37; H, 2.78; N, 10.40.
2.2. In-vitro anticancer screening
In vitro cytotoxicity was determined using a standard MTT
assay with protocol appropriate for the individual test system
(Denizot and Lang, 1986). The four human cancer cell lines
HeLa, MCF-7, HL-60 and HepG2, were cultured in thePlease cite this article in press as: Kumar, D. et al., Design, synthesis and cytotoxic ev
of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.07.001MEM medium supplemented with 10% FBS, 1% glutamine
and 50 mM/ml gentamicin sulfate in a CO2 incubator in a
humidiﬁed atmosphere of 5% CO2 and 95% air. The test com-
pounds were prepared prior to the experiment by dissolving in
0.1% DMSO and diluted with medium. The cells were then
exposed to different concentrations of drugs (1–100 mM) in
the volume of 100 mM/well. Cells in the control wells received
the same volume of medium containing 0.1% DMSO. After
24 h, the medium was removed and cell cultures were incu-
bated with 100 ml MTT reagent (1 mg/ml) for 5 h at 37 C.
The known number of cells (1.0 ± 105) was incubated in a
5% CO2 incubator at 37 C in the presence of different concen-
trations of test compounds. After 48 h of drug incubation, the
MTT solution was added in each well and absorbance was
recorded at 540 nm by an ELISA reader. The experiment
was performed in triplicate. Cell survival was calculated as
the percentage of MTT inhibition as % growth inhibi-
tion = 100  (mean OD of individual test Group/Mean OD
of each Control Group) · 100.
The IC50 values of the synthesized compounds 4a–j and
5a–d for four cell lines are summarized in Table 1.
3. Results and discussion
3.1. Synthesis
All the synthesized compounds were characterized by physio-
chemical and spectral data. The characteristic functional
groups present in the synthesized imidazolone fused quinazoli-
none derivatives are C‚O (imidazoline ring), C‚O (quinaz-
olinone ring), C‚N, C‚CAH, CAHAAr, CAOAFuran,
CABr, CACH3 and aromatic ring vibration. IR spectra
showed the appearance of peak at 3300–3475 cm1 indicating
the presence of the NAN group in imidazolone fused quinaz-
olinone ring in all the compounds. The appearance of peakaluation of novel imidazolone fused quinazolinone derivatives. Arabian Journal
6 D. Kumar et al.at 1500–1700 cm1 conﬁrmed C‚O in imidazoline and the
quinazolinone group in ﬁnal products. The peaks at 1300–
1500 cm1 ascertained the presence of the C‚N group. 1H
NMR spectra showed an intense signal at 6.83–7.86 due to
the presence of oleﬁnic proton in all the compounds. The
methyl group of quinazolinone ring led to a sharp singlet at
3–3.32 ppm which signiﬁed 3 protons. The proton present in
the aromatic ring was conﬁrmed by multiplet at 6–8 ppm. In
addition to these common groups, the proton of N (CH3)2
and OCH3 was also identiﬁed by the signal at 3–4 ppm in
compounds 4e, 4f and 4i. In mass spectra of the synthesized
compounds, the molecular ion was evident and its accurate
mass was measured. From the physiochemical, spectral and
elemental analysis data, all the synthesized compounds were
in conformity with structures envisaged.
3.2. In vitro anticancer screening
The synthesized compounds were evaluated for in vitro cyto-
toxic activity against various cell lines such as HeLa (cervical
cancer), MCF-7 (breast cancer), HL-60 (Human promyelo-
cytic leukemia) and HepG2 (Hepatocellular carcinoma) by
the MTT assay method. Cisplatin, one of the most effective
anticancer agents was used as a reference drug in this study.
The relationship between surviving fraction and drug concen-
tration was plotted to obtain the survival curve of all the can-
cer cell lines HeLa, MCF-7, HL-60 and HepG2. The response
parameter calculated was the IC50 values, which responds to
the concentration required for 50% inhibition of cell viability.
The in vitro cytotoxic activity of the synthesized compounds is
summarized in Table 1.
In in vitro cytotoxic study, the compounds substituted by
both the electron withdrawing groups like NO2, Cl and elec-
tron donating groups such as OCH3, OH, and NA(CH3)2
had shown remarkable inﬂuence in anticancer effect. It was
found that electron donating groups have profound effect than
the electron withdrawing groups. Among the tested com-
pounds, 4e exhibited maximum cytotoxic activity against
HeLa (IC50 41.8 lM) and is close to standard Cisplatin. The
para substituted analog had shown more effect than meta
substituted one. Among the compounds with electron with-
drawing group, 4g (IC50 71.4 lM) was more effective. The cell
viability was tested against MCF-7 and most of the com-
pounds showed signiﬁcant inhibitory concentration. Most sur-
prisingly, the compound 4e exhibited maximum cytotoxic
activity with IC50 8.9 lM. Apart from 4e, 4g (IC50 51.4 lM)
was also found to be active. Compounds 4e, 4i, 4f, 5b, 4g, 5a
and 4h, showed inhibitory concentration less than 50% which
showed that these compounds are active against HL-60 cell
line. This result indicated that synthesized compound 4e
(IC50 6.6 lM) has potency equivalent to the standard drug
Cisplatin. All quinazolinone derivatives showed potent to
moderate anti cancer activity against HepG2 cell line. The
inhibitory concentration for more than ﬁve compounds was
less than 50% (i.e. 4e, 4i, 4h, 5b, 4f and 4g) and among them,
compound 4e IC50 was 9.6 lM.
The following mechanism of action can be proposed for
quinazolinone derivatives since their chemical structure, in
some respect resembles Raltitrexed and Thymitaq which inhib-
its EGFR tyrosine kinase by binding to the adenosine triphos-
phate (ATP)-binding site of the enzyme. The epidermal growth
factor receptor (EGFR) is cellular trans-membrane tyrosinePlease cite this article in press as: Kumar, D. et al., Design, synthesis and cytotoxic ev
of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.07.001kinases that is over-expressed in a signiﬁcant number of
human tumors (e.g., breast, ovarian, colon, and prostate), their
expression levels often correlate with vascularity and is associ-
ated with poor prognosis in patients (Kersemaekers et al.,1999)
Thus the function of the EGFR tyrosine kinase in activating
the anti-apoptotic rap signal transduction cascade is inhibited,
and malignant cells are inhibited. The synthesized quinazoli-
none derivatives may be a selective inhibitor of the epidermal
growth factor receptor (EGFR) tyrosine kinase over expres-
sion through the inhibition of EGFR autophosphorylation
and EGF-stimulated signal transduction (Grifﬁn et al.,
1998). Furthermore, it can also be proposed that quinazoli-
nones may exert their antitumor activity through inhibition
of the DNA repair enzyme system. Enzyme-mediated repair
of strand lesions in DNA is an established mechanism for
resistance toward antitumor DNA-damaging drugs and radio-
therapy (Fricker, 2006; Grifﬁn et. al., 1998). Hence it can be
expected that these derivatives may inhibit the tumor cells by
both or any one of these mechanisms. However, a detailed
receptor study and DNA analysis are necessary to reach a con-
crete conclusion.4. Conclusions
Comprehensively, it is summarized that some of the quinazoli-
none derivatives are possessing prominent activity against cer-
vical cancer, breast cancer, leukemia and hepatocellular
cancer. Among the cell lines tested, these derivatives have
shown profound effect against HL-60 and HepG2. Most
remarkably, compound 4e is having three folds higher activity
than Cisplatin against breast cancer, twofold greater than that
of standard against liver cancer whereas against cervical and
blood cancer the activity is equivalent to standard. Structure
activity relationship of the compounds showed that the elec-
tron donating group enhances the activity while the electron
withdrawing group decreases the activity. The prominent cyto-
toxic effect of 4e may be due to the presence of electron donor
at para carbon as compared to other derivatives except 4f. It
can also be justiﬁed that the para substituent may not have
more steric hindrance as the ortho group does in general.
However, extensive pharmacological and toxicological studies
will explore the therapeutic beneﬁt of the tested quinazolinone
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